Den 20 oktober presenterade Karin Agerman, Chief Research & Development Officer på CombiGene på ATMP Swedens webinar Manufacturing of Gene Therapy Products in Sweden
On October 20, Karin Agerman, Chief Research & Development Officer at CombiGene presented on ATMP Sweden's webinar Manufacturing of Gene Therapy Products in Sweden. Karin gave her views on the production of gene therapies in Sweden under the heading A small...read more
On October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna
On October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna's digital event. If you didn't have the opportunity to follow the presentation live, you can now view it here...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.